Pediatric Safety Follow-up Study of Prior Treatment With Romosozumab for Osteogenesis Imperfecta
← catalyst calendarNCT07366086 · readout in 608 d
Sponsored by Amgen (industry) · AMGN — their whole pipeline →.
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Na · None · Supportive care
Enrollment
71estimated
Sites
4
Countries
Germany, Japan, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-03-18 | actual | When the study began enrolling |
| Primary completion | 2028-04-19 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-04-19 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Osteogenesis Imperfecta
Interventions
- Dietary supplement: Vitamin D
- Dietary supplement: Calcium
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Adverse Events (AEs)
measured Up to 9 months
Permalink · AMGN's whole pipeline · Catalyst calendar · Every registered study · What changed